Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Short-term Investments: 2016-2019

Historic Short-term Investments for Akebia Therapeutics (AKBA) over the last 4 years, with Dec 2019 value amounting to $245,000.

  • Akebia Therapeutics' Short-term Investments fell 99.85% to $245,000 in Q4 2019 from the same period last year, while for Dec 2019 it was $245,000, marking a year-over-year decrease of 99.85%. This contributed to the annual value of $245,000 for FY2019, which is 99.85% down from last year.
  • Akebia Therapeutics' Short-term Investments amounted to $245,000 in Q4 2019, which was down 98.92% from $22.7 million recorded in Q3 2019.
  • Over the past 5 years, Akebia Therapeutics' Short-term Investments peaked at $240.1 million during Q3 2017, and registered a low of $245,000 during Q4 2019.
  • In the last 3 years, Akebia Therapeutics' Short-term Investments had a median value of $169.7 million in 2017 and averaged $151.1 million.
  • Its Short-term Investments has fluctuated over the past 5 years, first surged by 151.44% in 2017, then slumped by 99.85% in 2019.
  • Over the past 4 years, Akebia Therapeutics' Short-term Investments (Quarterly) stood at $73.0 million in 2016, then skyrocketed by 139.43% to $174.8 million in 2017, then declined by 9.43% to $158.3 million in 2018, then slumped by 99.85% to $245,000 in 2019.
  • Its Short-term Investments was $245,000 in Q4 2019, compared to $22.7 million in Q3 2019 and $49.6 million in Q2 2019.